Meeting
2023 ASCO Genitourinary Cancers Symposium
The impact of blue light cystoscopy use among patients with non-muscle invasive bladder cancer in an equal access setting.
Authors
Sanjay Das
UCLA Health, Department of Urology, Los Angeles, CA
Sanjay Das , Lin Gu , Claire Trustram Eve , Joshua Parrish , Amanda Marie De Hoedt , Chad McKee , William Aronson , Stephen J. Freedland , Stephen B. Williams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 461)
DOI
10.1200/JCO.2023.41.6_suppl.461
Abstract #
461
Poster Bd #
H2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
First Author: Neeta DSouza
Poster
2023 ASCO Genitourinary Cancers Symposium
Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development.
First Author: Christopher Gaffney
Poster
2021 Genitourinary Cancers Symposium
Is there a role for urine cytology following BCG therapy for non-muscle-invasive bladder cancer (NMIBC)?
First Author: Sarah Prattley
Poster
2021 Genitourinary Cancers Symposium
Does the diagnostic modality for upper tract urothelial carcinoma prior to radical nephroureterectomy influence the risk of subsequent intravesical recurrence?
First Author: Tanner Miest